Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the stock.

SYRS has been the subject of several other reports. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Price Performance

SYRS stock opened at $0.08 on Thursday. Syros Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $6.93. The firm has a market cap of $2.05 million, a PE ratio of -0.03 and a beta of 1.31. The firm has a 50 day simple moving average of $0.17 and a 200 day simple moving average of $0.92.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several hedge funds have recently made changes to their positions in SYRS. Two Sigma Securities LLC purchased a new stake in shares of Syros Pharmaceuticals in the 4th quarter valued at approximately $25,000. GSA Capital Partners LLP acquired a new position in Syros Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Finally, Exome Asset Management LLC increased its stake in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares during the period. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.